Mechanisms and rescue strategies of calcineurin inhibitor mediated tolerance abrogation induced by anti-CD4 mAb treatment

American Journal of Transplantation

Volumn 13, Issue 9, 2013, Pages 2308-2321

  Siepert, A ^a   Brosel S ^b   Vogt, K ^b   Ahrlich, S ^b   Schmitt Knosalla, I ^b   Loddenkemper, C ^b   Kuhl A ^b   Baumgrass, R ^c   Gerstmayer, B ^d   Tomiuk, S ^d   Tiedge, M ^a   Viklicky O ^e   Brabcova, I ^e   Nizze, H ^a   Lehmann, M ^a   Volk, H D ^b   Sawitzki, B ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c German Rheumatology Research Center   (Germany)

^d MILTENYI BIOTEC GMBH   (Germany)

^e INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Anti CD4mAb; calcineurin inhibitors; chronic rejection; regulatory T cells; tolerance; transplantation

Indexed keywords

ALLOANTIBODY; CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C3D; CXCL13 CHEMOKINE; CYCLOSPORIN A; IMMUNOGLOBULIN G; OKT 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CELL INFILTRATION; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; GRAFT SURVIVAL; HUMORAL IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; MALE; MESANGIUM CELL; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPLEEN CELL;

ANTI-CD4MAB; CALCINEURIN INHIBITORS; CHRONIC REJECTION; REGULATORY T CELLS; TOLERANCE; TRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CALCINEURIN; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINE CXCL13; CYCLOSPORINE; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MALE; RATS; RATS, INBRED LEW;

EID: 84883451839     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12352     Document Type: Article

References (65)

1. Matthews JB, Ramos E, Bluestone JA., Clinical trials of transplant tolerance: Slow but steady progress. Am J Transplant 2003; 3: 794-803.
2. Hill P, Gagliardini E, Ruggenenti P, Remuzzi G., Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy. Nephrol Dial Transplant 2005; 20: 1741-1744.
3. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465-474.
4. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358: 353-361.
5. Leventhal J, Abecassis M, Miller J, et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Trans Med 2012; 4: 124-128.
6. Leventhal J, Abecassis M, Miller J, et al. Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: Durable chimerism predicts outcome. Transplantation 2013; 95: 169-176.
7. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008; 358: 362-368.
8. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant 2012; 12: 1133-1145.
9. Andree H, Nickel P, Nasiadko C, et al. Identification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank. J Am Soc Nephrol 2006; 17: 573-580.
10. Nickel P, Presber F, Bold G, et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation 2004; 78: 1640-1646.
11. Valujskikh A., The challenge of inhibiting alloreactive T-cell memory. Am J Transplant 2006; 6: 647-651.
12. Siepert A, Ahrlich S, Vogt K, et al. Permanent CNI treatment for prevention of renal allograft rejection in sensitized host can be replaced by regulatory T cells. Am J Transplant 2012. doi: 10.1111./j.1600-6143.2012.04143.x
13. Casey M, Meier-Kriesche H., Calcineurin inhibitors in kidney transplantation: Friend or foe ? Curr Opin Nephrol Hypertens 2011; 20: 610-615.
14. Hernández D, Miquel R, Porrini E, et al. Randomized controled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. Tranplantation 2007; 84: 706-714.
15. Weir M, Ward M, Blahut S, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567-1573.
16. Izawa A, Sayegh MH, Chandraker A., The antagonism of calcineurin inhibitors and costimulatory blockers: Fact or fiction ? Transplant Proc 2004; 36: 570S-573S.
17. Blaha P, Bigenzahn S, Koporc Z, et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 2003; 101: 2886-2893.
18. Lan F, Hayamizu K, Strober S., Cyclosporine facilitates chimeric and inhibits nonchimeric tolerance after posttransplant total lymphoid irradiation. Transplantation 2000; 69: 649-655.
19. Taylor PA, Lees CJ, Wilson JM, et al. Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions. Blood 2002; 100: 3400-3407.
20. Sho M, Sandner SE, Najafian N, et al. New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg 2002; 236: 667-675.
21. Smiley ST, Csizmadia V, Gao W, Turka LA, Hancock WW., Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: Implications for tolerance induction. Transplantation 2000; 70: 415-419.
22. Hamano K, Ito H, Bushell A, Wood KJ, Esato K., The induction of operational tolerance is not prevented by simultaneous administration of cyclosporin A1. Transpl Int 1997; 10: 293-298.
23. Moffatt SD, Metcalfe SM., Comparison between tacrolimus and cyclosporine as immunosuppressive agents compatible with tolerance induction by CD4/CD8 blockade. Transplantation 2000; 69: 1724-1726.
24. Olausson M, Lukes D, Norrby J, et al. Antithymocyte globulin and cyclosporin A are synergistic in an experimental transplantation tolerance model in the rat. Scand J Immunol 1999; 49: 38-44.
25. Yang CP, Shittu E, Bell EB., Specific B cell tolerance is induced by cyclosporin A plus donor-specific blood transfusion pretreatment: Prolonged survival of MHC class I disparate cardiac allografts. J Immunol 2000; 164: 2427-2432.
26. Nomoto K, Eto M, Yanaga K, Nishimura Y, Maeda T, Nomoto K., Interference with cyclophosphamide-induced skin allograft tolerance by cyclosporin A. J Immunol 1992; 149: 2668-2674.
27. Perico N, Imberti O, Bontempelli M, Remuzzi G., Immunosuppressive therapy abrogates unresponsiveness to renal allograft induced by thymic recognition of donor antigens. J Am Soc Nephrol 1995; 5: 1618-1623.
28. Kawai M, Kitade H, Mathieu C, Waer M, Pirenne J., Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T cells in vivo. Transplantation 2005; 79: 1073-1077.
29. Tsui TY, Jager MD, Deiwick A, et al. Delayed low-level calcineurin inhibition promotes allospecific tolerance induction by posttransplantation donor leukocyte infusion. Transplantation 2002; 73: 1325-1332.
30. Bohne F, Martinez-Llordella M, Lozano JJ, et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest 2012; 122: 368-382.
31. Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 2007; 104: 15448-15453.
32. Londono MC, Lopez MC, Sanchez-Fueyo A., Minimization of immunosuppression in adult liver transplantation: New strategies and tools. Current opinion in organ transplantation 2010 Sep 30. [Epub ahead of print]
33. Martinez-Llordella M, Lozano JJ, Puig-Pey I, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118: 2845-2857.
34. Newell KA, Asare A, Kirk AD, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120: 1836-1847.
35. Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010; 120: 1848-1861.
36. Noris M, Casiraghi F, Todeschini M, et al. Regulatory T cells and T cell depletion: Role of immunosuppressive drugs. J Am Soc Nephrol 2007; 18: 1007-1018.
37. Pascual J, Bloom D, Torrealba J, et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: Clinical outcomes and effect on T-regulatory cells. Am J Transplant 2008; 8: 1529-1536.
38. Lee S., An improved technique of renal transplantation in the rat. Surgery 1967; 61: 771-773.
39. Lehmann M, Graser E, Risch K, et al. Anti-CD4 monoclonal antibody-induced allograft tolerance in rats despite persistence of donor-reactive T cells. Transplantation 1997; 64: 1181-1187.
40. Lehmann M, Sternkopf F, Metz F, et al. Induction of long-term survival of rat skin allografts by a novel, highly efficient anti-CD4 monoclonal antibody. Transplantation 1992; 54: 959-962.
41. Sawitzki B, Amersi F, Ritter T, et al. Upregulation of bag-1 by ex vivo gene transfer protects rat livers from ischemia/reperfusion injury. Hum Gene Ther 2002; 13: 1495-1504.
42. Sawitzki B, Kieselbach B, Fisser M, et al. IFN-gamma regulation in anti-CD4 antibody-induced T cell unresponsiveness. J Am Soc Nephrol 2004; 15: 695-703.
43. Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation and mobility in keratinocytes: A potential role in psoriasis. Eur J Immunol 2006; 36: 1309-1323.
44. Sawitzki B, Lehmann M, Vogt K, et al. Bag-1 up-regulation in anti-CD4 mAb treated allo-activated T cells confers resistance to apoptosis. Eur J Immunol 2002; 32: 800-809.
45. Binder J, Lehmann M, Graser E, et al. The effects of nondepleting CD4 targeted therapy in presensitized rat recipients of cardiac allografts. Transplantation 1996; 61: 804-811.
46. Onodera K, Lehmann M, Akalin E, Volk HD, Sayegh MH, Kupiec-Weglinski JW., Induction of "infectious" tolerance to MHC-incompatible cardiac allografts in CD4 monoclonal antibody-treated sensitized rat recipients. J immunol 1996; 157: 1944-1950.
47. Zhai Y, Shen XD, Lehmann M, Busuttil R, Volk HD, Kupiec-Weglinski JW., T cell subsets and in vitro immune regulation in "infectious" transplantation tolerance. J Immunol 2001; 167: 4814-4820.
48. Adams AB, Shirasugi N, Jones TR, et al. Conventional immunosuppression is compatible with costimulation blockade-based, mixed chimerism tolerance induction. Am J Transplant 2003; 3: 895-901.
49. Ebisuno Y, Tanaka T, Kanemitsu N, et al. Cutting edge: The B cell chemokine CXC chemokine ligand 13/B lymphocyte chemoattractant is expressed in the high endothelial venules of lymph nodes and Peyer's patches and affects B cell trafficking across high endothelial venules. J Immunol 2003; 171: 1642-1646.
50. Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B., B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 1998; 187: 655-660.
51. Forster R, Mattis AE, Kremmer E, Wolf E, Brem G, Lipp M., A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 1996; 87: 1037-1047.
52. Shi K, Hayashida K, Kaneko M, et al. Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol 2001; 166: 650-655.
53. Steinmetz OM, Panzer U, Kneissler U, et al. BCA-1/CXCL13 expression is associated with CXCR5-positive B-cell cluster formation in acute renal transplant rejection. Kidney Int 2005; 67: 1616-1621.
54. Heller F, Lindenmeyer MT, Cohen CD, et al. The contribution of B cells to renal interstitial inflammation. Am J Pathol 2007; 170: 457-468.
55. Colvin RB, Smith RN., Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5: 807-817.
56. Noorchashm H, Reed AJ, Rostami SY, et al. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J Immunol 2006; 177: 7715-7722.
57. Kelishadi SS, Azimzadeh AM, Zhang T, et al. Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys. J Clin Invest 2010; 120: 1275-1284.
58. Heidt S, Hester J, Shankar S, Friend PJ, Wood KJ., B-cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells. Am J Transplant 2012; 12: 1784-1792.
59. Le Texier L, Thebault P, Lavault A, et al. Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile. Am J Transplant 2011; 11: 429-438.
60. Newell KA, Asare A, Kirk AD, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 120: 1836-1847.
61. Tseng J, Lee YJ, Eisfelder BJ, Clark MR., The B cell antigen receptor complex: Mechanisms and implications of tyrosine kinase activation. Immunol Res 1994; 13: 299-310.
62. Chu PG, Arber DA., CD79: A review. Appl Immunohistochem Mol Morphol 2001; 9: 97-106.
63. Arjomand J, Cole S, Evans CJ., Novel orphanin FQ/nociceptin transcripts are expressed in human immune cells. J Neuroimmunol 2002; 130: 100-108.
64. Anton B, Leff P, Meissler JJ, et al. Nociceptin/orphanin FQ suppresses adaptive immune responses in vivo and at picomolar levels in vitro. J Neuroimmune Pharmacol 2010; 5: 143-154.
65. Waits PS, Purcell WM, Fulford AJ, McLeod JD., Nociceptin/orphanin FQ modulates human T cell function in vitro. J Neuroimmunol 2004; 149: 110-120.